Stemtech Corp
Stemtech is a global network marketing company that develops and sells products it describes as stem cell enhancers, intended to support wellness by helping the body maintain healthy stem cell physiology. Its products are marketed internationally through subsidiaries and independent distributors. Brands include RCM System, stemrelease3, StemFlo, MigraStem, OraStem oral health care and Cellect One skincare, including Rapid Renew Stem Cell Peptide Night Cream and Shield HOCL skin care product. Stemtech is headquartered in Naples, Florida.
No SEC Form 4 filings for $STEK in the last 30 days.
See all $STEK insider activity →Stemtech reported 3Q 2026 revenue of $282.48K, down 67% YoY, citing a smaller distributor base. Net income improved to a loss of $478.58K, as lower expenses offset declining gross profit. The company is working to recruit and re-engage distributors and has restored product supply.
Stemtech Corporation (OTCID:STEK) said in its 2025 year-in-review letter that 2025 revenue fell due to a temporary inventory funding shortage that limited product availability, not underlying demand. The company reported a $3.3 million net loss ($0.03/share) and cut operating expenses by $2.3 million (37.7%). It secured dedicated inventory funding and expanded global operations via joint ventures and new market initiatives, including Asia focus.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning STEK (Stemtech Corp). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent STEK coverage spans earnings and financial news.
The sharp revenue drop and continued losses suggest downward pressure on the stock.
Secured inventory funding is positioned as the key fix to a previously supply-driven revenue decline, potentially improving near-term fulfillment and revenue conversion.
AlphAI scores every news story that mentions STEK with an AI model for sentiment and relevance, and aggregates insider trades from Stemtech Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Stemtech reported 3Q 2026 revenue of $282.48K, down 67% YoY, citing a smaller distributor base. Net income improved to a loss of $478.58K, as lower expenses offset declining gross profit. The company is working to recruit and re-engage distributors and has restored product supply.
Stemtech Corporation (OTCID:STEK) said in its 2025 year-in-review letter that 2025 revenue fell due to a temporary inventory funding shortage that limited product availability, not underlying demand. The company reported a $3.3 million net loss ($0.03/share) and cut operating expenses by $2.3 million (37.7%). It secured dedicated inventory funding and expanded global operations via joint ventures and new market initiatives, including Asia focus.
